2012 Fiscal Year Final Research Report
The identification of miR-gene pathway regulating the sensitivity of platinum agentsfor gastric cancer and its clinical applicatio
| Project/Area Number |
23659656
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
BABA Hideo 熊本大学, 大学院・生命科学研究部, 教授 (20240905)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
WATANABE Masayuki 熊本大学, 大学院・生命科学研究部, 准教授 (80254639)
HIRASHIMA Kotaro 熊本大学, 医学部附属病院, 非常勤診療医師 (10594468)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | 塩基修復遺伝子 / 白金製剤耐性 / microRNA / 胃癌 |
|---|
| Research Abstract |
A platinum agent, cisplatin (CDDP) plus S-1 is the standard regimenfor unresectable or recurrent gastric cancer. However, grade 3/4 adverse events arefrequently observed in patients received with CDDP based regimen. Oxaliplatin (L-OHP)is a third-generation platinum compound and the non-inferiority of L-OHP-based regimensto CDDP-based regimen was demonstrated in large phase III study for esophagogastric cancer.Furthermore, L-OHP is associated with less toxicity and better tolerability, especiallyin older patients and significant survival benefit over CDDP. In the current study, weexamined the expression of the novel genes regulating the sensitivity for platinum agentsin clinical samples and whether these genes expression is associated with the sensitivityto CDDP using by clinical samples.
|
-
[Journal Article] Phase II trial of alternatingmFOLFOX6 and FOLFIRI regimens in thefirst-line treatment for unresectableor metastatic colorectal cancer(KSCC0701).2013
Author(s)
Oki E, Emi Y, Akagi Y, Tokunaga S,Sadanaga N, Tanaka T, Ogata Y, SaekiH, Kakeji Y, Baba H, Nishimaki T,Natsugoe S, Shirouzu K, Maehara Y
-
Journal Title
Kyushu Study Group of Clinical Cancer.Oncology
Volume: 84
Pages: 233-9
DOI
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
